AFP Blood Test: Why Your Doctor Checks for Liver Cancer Every 6 Months

If you have cirrhosis, your doctor should be checking your AFP level and doing a liver ultrasound every 6 months — and if they're not, you need to ask why. AFP (alpha-fetoprotein) is a blood test that screens for hepatocellular carcinoma (HCC) — the most common type of primary liver cancer — which develops in 1–6% of cirrhosis patients every year. Finding it early is the difference between a curable cancer and a fatal one.

Despite this, screening rates are shockingly low. Studies consistently show that fewer than 25% of eligible cirrhosis patients receive consistent HCC surveillance at the recommended intervals. That means three out of four patients who should be getting this test every 6 months are not getting it — or not getting it on schedule. Many don't know what AFP is, why it matters, or that they're supposed to be getting it.

This article changes that. Here's what AFP measures, what the numbers mean, why the 6-month interval matters, what happens when AFP is elevated, and what you should be tracking.

What AFP is and where it comes from

Alpha-fetoprotein is a protein produced primarily by the fetal liver during pregnancy — it's one of the main proteins in fetal blood. After birth, AFP production drops rapidly, and in healthy adults, AFP levels are very low (typically less than 10 ng/mL). Your adult liver makes only trace amounts.

When liver cells become cancerous, they can revert to producing AFP at much higher levels — essentially behaving like fetal liver cells in their protein production. This is why AFP in an adult's blood can serve as a tumor marker: elevated levels suggest that liver cells are growing abnormally.

It's not a perfect marker — not all liver cancers produce AFP (about 30–40% of HCC tumors are "AFP-negative"), and AFP can be elevated for reasons other than cancer. But combined with ultrasound, it remains the cornerstone of HCC surveillance worldwide.

Normal AFP levels and what elevated numbers mean

Important nuances: AFP can be mildly elevated (10–20 ng/mL) in patients with active hepatitis (inflammation stimulates AFP production), in hepatitis B carriers without cancer, during liver regeneration after injury, and during pregnancy (normally elevated). This is why a single mildly elevated AFP doesn't automatically mean cancer — it means "investigate further." The key is the trend: a steadily rising AFP over serial measurements, even if each individual level is only moderately elevated, is more concerning than a single spike that returns to baseline.

Why screening is done every 6 months — not annually, not quarterly

The 6-month interval isn't arbitrary. It's based on the average doubling time of hepatocellular carcinoma — the time it takes for an HCC tumor to double in size. HCC has a median tumor doubling time of approximately 4–6 months. Screening every 6 months is designed to catch tumors while they're still small enough (typically within Milan criteria — single tumor ≤5 cm, or up to 3 tumors each ≤3 cm) to be treated curatively.

Why not more frequently? Annual screening misses the window — a tumor that wasn't visible 12 months ago may have grown beyond curative treatment by the time the next screen occurs. Quarterly screening (every 3 months) is more sensitive but hasn't been shown to improve survival in studies, generates more false positives and unnecessary invasive workups, and increases cost and patient burden without clear outcome benefit.

The 6-month interval represents the sweet spot: frequent enough to catch most tumors at a treatable stage, without creating excessive false-positive burden.

What screening actually involves — AFP plus ultrasound

The recommended HCC surveillance protocol (per AASLD, EASL, and virtually all international guidelines) is AFP blood test + abdominal ultrasound every 6 months. Both together.

Why both? Neither test alone is sufficient. Ultrasound alone misses some tumors — particularly in obese patients, in livers with nodular cirrhotic texture (which makes small tumors hard to distinguish from surrounding nodules), and in tumors located in technically difficult positions. Ultrasound sensitivity for early-stage HCC is approximately 60–70%. AFP alone misses the 30–40% of HCC tumors that don't produce AFP. Combined, ultrasound + AFP detects more tumors at earlier stages than either test alone. A meta-analysis showed that adding AFP to ultrasound increases sensitivity for early HCC from 63% to 73% without significantly increasing false positive rates.

Your surveillance appointment should include both: a blood draw for AFP (results in 1–3 days) and an abdominal ultrasound (performed by a sonographer, reviewed by a radiologist, results in 1–7 days). Some centers do both on the same day. Others schedule them separately. Either approach is fine — what matters is that both happen every 6 months.

Log every screening in the LiverTracker imaging tracker — date, AFP result, ultrasound findings, and next-due date. Never miss a screening because you forgot when it was scheduled.

Who needs HCC screening

The short answer: all patients with cirrhosis from any cause. The slightly longer answer includes specific populations:

• All cirrhosis patients (any etiology — alcohol, NASH, hepatitis B, hepatitis C, autoimmune, PBC, PSC, hemochromatosis, etc.) — the annual HCC incidence is 1–6%.

• Chronic hepatitis B carriers without cirrhosis — certain high-risk groups (Asian males over 40, Asian females over 50, Africans over 20, anyone with a family history of HCC, high HBV viral load) should be screened even without established cirrhosis, because hepatitis B can cause HCC without going through the cirrhosis stage.

• Patients with advanced fibrosis (F3) — some guidelines recommend starting screening at F3 rather than waiting for F4, as HCC risk begins to rise before cirrhosis is formally established.

• Post-transplant patients — if transplanted for HCC, surveillance continues because of recurrence risk.

If you have cirrhosis and your doctor hasn't mentioned HCC screening — bring it up at your next appointment. This is one area where patient advocacy can literally save your life.

What happens when AFP is elevated or a mass is found

An elevated AFP or a suspicious finding on ultrasound triggers a diagnostic workup — not a cancer diagnosis. The next steps are cross-sectional imaging (usually within 2–4 weeks): a multiphase CT scan or a multiphase MRI with contrast. These specialized scans evaluate the blood flow characteristics of any liver mass. HCC has a characteristic imaging pattern — arterial hyperenhancement (the tumor lights up during the arterial phase of contrast injection) followed by washout (the tumor becomes darker than surrounding liver in later phases). This pattern is so specific that in the right clinical context, it confirms HCC without needing a biopsy.

If imaging confirms HCC, the tumor is staged using the Barcelona Clinic Liver Cancer (BCLC) system, which determines treatment based on tumor size and number, liver function (Child-Pugh class), overall health and performance status, and portal vein involvement.

Treatment options for early-stage HCC include surgical resection (removing the tumor), liver transplant (removes both the tumor and the diseased liver), ablation (destroying the tumor with heat, cold, or radiofrequency energy), and transarterial chemoembolization (TACE — delivering chemotherapy directly to the tumor). Five-year survival for early-stage HCC detected through surveillance is approximately 50–70%. For late-stage HCC found because of symptoms (not screening), 5-year survival drops dramatically to roughly 10–20%. This survival gap is the entire argument for consistent 6-month screening.

Tracking your AFP over time

A single AFP value is useful, but the trend over time is more valuable — because a gradually rising AFP, even if each individual level is below the "concerning" threshold, can signal a developing tumor months before it becomes visible on ultrasound.

Example: AFP measured at 5, 7, 12, 18, 26 over five consecutive 6-month screenings. Each individual result might not trigger alarm — 5 is normal, 7 is normal, 12 is borderline. But the trend — steadily doubling — is a red flag that warrants earlier imaging, even before the number crosses the traditional 20 ng/mL threshold.

Upload every lab report to LiverTracker. AFP is extracted and tracked on your visual trend charts alongside all your other liver values. A rising AFP trend on your chart is visible at a glance — and it's exactly the kind of pattern that catches tumors early. Share your trends with your hepatologist before every surveillance appointment.

The screening gap — and what you can do about it

The data on HCC surveillance adherence is sobering. Studies consistently show that only 20–25% of eligible cirrhosis patients receive biannual surveillance at the recommended frequency. Barriers include patients not knowing they need screening (the most common barrier), inconsistent physician ordering (busy practices, missed follow-ups), patient barriers (transportation, insurance, scheduling difficulties), and a lack of systematic recall programs at many hepatology practices.

What you can do: ask your hepatologist to confirm that you're enrolled in their HCC surveillance program. Set your own 6-month reminders (phone calendar, recurring alerts). Track your screening dates in the LiverTracker imaging tracker — including the next-due date. If your next screening is overdue, call the office proactively. Don't wait for them to call you.

This is an area where being an informed, proactive patient can genuinely save your life. The screening exists. It works. But only if it actually happens every 6 months.

Frequently asked questions

Does a normal AFP mean I don't have liver cancer?

Not necessarily. About 30–40% of HCC tumors don't produce AFP at all — these are "AFP-negative" tumors. This is exactly why AFP alone isn't sufficient for screening — it must be combined with ultrasound. A normal AFP with a normal ultrasound is reassuring. A normal AFP with a suspicious ultrasound finding still requires further workup. Never rely on AFP alone.

My AFP is slightly elevated (12 ng/mL). Should I panic?

No. Mildly elevated AFP (10–20 ng/mL) is common in patients with active hepatitis, liver regeneration, or chronic hepatitis B — without any cancer. The response to a mildly elevated AFP is to recheck it in 3 months and watch the trend. If it returns to normal — likely not cancer. If it's rising — further imaging is warranted. A single mildly elevated result is not a cancer diagnosis.

Why every 6 months? Can't I do it annually?

The 6-month interval is based on HCC tumor doubling time (~4–6 months). Annual screening misses the window for early detection — a tumor invisible 12 months ago may have grown beyond curative treatment by the next screen. Studies show that 6-month surveillance detects HCC at earlier, more treatable stages compared to annual surveillance. The slight inconvenience of biannual screening translates to significantly better survival.

What other tests screen for liver cancer besides AFP?

Newer biomarkers are being studied and some are entering clinical use. AFP-L3 (a sub-fraction of AFP that's more specific to HCC), DCP (des-gamma-carboxyprothrombin, also called PIVKA-II), and the GALAD score (combining Gender, Age, AFP-L3, AFP, and DCP into a composite score) all show promise for improving HCC detection. Some centers already use GALAD scoring alongside standard AFP + ultrasound. Ask your hepatologist whether these newer markers are available and appropriate for your situation.

I had hepatitis C and was cured. Do I still need screening?

If you have cirrhosis — yes, indefinitely. Curing hepatitis C reduces but does not eliminate HCC risk. Patients with established cirrhosis who achieve SVR (viral cure) still have an annual HCC risk of approximately 1–2% — lower than before treatment, but not zero. Screening continues every 6 months for life. If you had hepatitis C without cirrhosis and achieved SVR, the risk drops much further and screening may not be needed — discuss with your hepatologist.

Can AFP detect other cancers?

Yes — AFP can be elevated in germ cell tumors (testicular cancer, ovarian cancer), gastric cancer with hepatoid differentiation, and rarely other cancers with hepatic metastases. In the context of cirrhosis, the assumption is that elevated AFP relates to HCC until proven otherwise — but your doctor may consider other possibilities depending on your clinical situation.

The AFP test takes one blood draw. The ultrasound takes 15 minutes. Together, every 6 months, they're your early warning system for a cancer that's curable when caught early and fatal when caught late. Don't skip it. Don't delay it. Don't assume someone else is keeping track.

→ Log Your Screenings

→ Start Tracking Free

→ Calculate Your MELD Score

Medical Disclaimer: This article is for informational and educational purposes only. HCC surveillance protocols should be individualized by your hepatologist. Elevated AFP does not automatically indicate cancer — further evaluation is always needed. Visit livertracker.com/medical-disclaimer.